Chronic Hepatitis C and Antiviral Treatment Regimens: Where Can Psychology Contribute?

Autor/inn/en	Evon, Donna M.; Golin, Carol E.; Fried, Michael W.; Keefe, Francis J.
Titel	Chronic Hepatitis C and Antiviral Treatment Regimens: Where Can Psychology Contribute?
Quelle	In: Journal of Consulting and Clinical Psychology, 81 (2013) 2, S.361-374 (14 Seiten) PDF als Volltext Verfügbarkeit
Sprache	englisch
Dokumenttyp	gedruckt; online; Zeitschriftenaufsatz
ISSN	0022-006X
DOI	10.1037/a0029030
Schlagwörter	Public Health; Mental Health; Quality of Life; Drinking; Clinical Psychology; Drug Therapy; Patients; Psychologists; Outcomes of Treatment; Diseases; Coping; Racial Discrimination; Incidence; Intervention; Symptoms (Individual Disorders) + Suchen Sie Ihr Suchwort? Gesundheitswesen; Psychohygiene; Lebensqualität; Trinken; Klinische Psychologie; Patient; Psychologist; Psychologe; Psychologin; Disease; Krankheit; Bewältigung; Racial bias; Rassismus; Vorkommen; Psychiatrische Symptomatik
Abstract	Objective: Our goal was to evaluate the existing literature on psychological, social, and behavioral aspects of chronic hepatitis C viral (HCV) infection and antiviral treatment; provide the state of the behavioral science in areas that presently hinder HCV-related health outcomes; and make recommendations for areas in which clinical psychology can make significant contributions. Method: The extant literature on HCV and antiviral therapy was reviewed as related to biopsychosocial factors such as mental health, substance/alcohol use, quality of life, coping, stigma, racial disparities, side effects, treatment adherence, integrated care, and psychological interventions. Results: For reasons that have not been well elucidated, individuals infected with HCV experience psychological and somatic problems and report poor health-related quality of life. Preexisting conditions, including poor mental health and alcohol/substance use, can interfere with access to and successful completion of HCV treatment. Perceived stigma is highly prevalent and associated with psychological distress. Racial disparities exist for HCV prevalence, treatment uptake, and treatment success. During HCV treatment, patients experience exacerbation of symptoms, treatment side effects, and poorer quality of life, making it difficult to complete treatment. Despite pharmacological advances in HCV treatment, improvements in clinical and public health outcomes have not been realized. The reasons for this lack of impact are multifactorial, but include suboptimal referral and access to care for many patients, treatment-related side effects, treatment nonadherence, and lack of empirically based approaches. Conclusions: Biomedical advances in HCV and antiviral treatment have created a fertile field in which psychologists are uniquely positioned to make important contributions to HCV management and treatment. (Contains 1 figure.) (As Provided).
Anmerkungen	American Psychological Association. Journals Department, 750 First Street NE, Washington, DC 20002-4242. Tel: 800-374-2721; Tel: 202-336-5510; Fax: 202-336-5502; e-mail: order@apa.org; Web site: http://www.apa.org/publications
Erfasst von	ERIC (Education Resources Information Center), Washington, DC
Update	2017/4/10